Aligos Therapeutics (ALGS) vs Evaxion A/S (EVAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aligos Therapeutics (ALGS) has outperformed Evaxion A/S (EVAX) over the past year, losing 46.5% versus a loss of 51.5%. Over five years, ALGS leads with a -98.7% price change compared with -99.2% for EVAX. Aligos Therapeutics is the larger company by market cap ($33.2 million vs $27.5 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALGS | EVAX |
|---|---|---|
| Share price | $5.31 | $3.05 |
| Market cap | $33.16M | $27.52M |
| 1-day change | -0.19% | -2.87% |
| YTD return | -43.03% | -36.06% |
| 1-year return | -46.53% | -51.51% |
| 5-year return | -98.66% | -99.23% |
| EPS (TTM) | $-7.33 | $-0.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.69 | $12.15 |
| 52-week low | $3.98 | $2.77 |
| Distance from 52-week high | -61.21% | -74.90% |
| Analyst consensus | none | none |
| Avg. price target upside | +886.44% | +268.85% |
| Average volume | 88.98K | 200.14K |
| Shares outstanding | 5.44M | 9.02M |
| Employees | 82 | 46 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aligos Therapeutics
ALGS stock →Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.
Healthcare · Biotechnology · 82 employees
About Evaxion A/S
EVAX stock →Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia.
Healthcare · Biotechnology · 46 employees
ALGS vs EVAX FAQ
Which is bigger, Aligos Therapeutics or Evaxion A/S?
Aligos Therapeutics (ALGS) is larger, with a market capitalization of $33.16M compared with $27.52M for Evaxion A/S (EVAX).
Which stock has performed better over the past year, ALGS or EVAX?
ALGS returned -46.53% over the past 12 months, compared with -51.51% for EVAX (price return, excluding dividends). Past performance does not predict future results.
Are Aligos Therapeutics and Evaxion A/S in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.